the two co-founders of hepalink are both senior experts in biosaccharide chemistry, and have in-depth understanding of the significant role of biosaccharide chemistry in immunoregulation. immunological imbalances are the leading cause of cardiovascular disease and tumor formation, and the clinical demand for these two major diseases are left unmet.
after years of hard work, hepalink has built a complete heparin industrial chain, which has become a healthy business portfolio that helps millions of global patients every year and creates steadily growing value for investors.
quality is the lifeblood of hepalink. valuing quality is why we can survive and thrive and how we offer our products and services. in light of china’s gmp standard, usa’s cgmp standard, and ichq7a standard recognized by ema and coordinated organizations, we have established a sound, strict and comprehensive system for quality control andassurance. we firmly stick to the “quality first” principle by examining every part of the production and operation activities, including: raw materials, inventory, production, testing, sales, verification and training in the advanced quality testing laboratory. in addition, all employees of hepalink follow the company guideline that all actions are controllable and traceable so that we can provide long-term and stable supplies that meet the quality standards set by all drug policies and customer requirements.